Engineering the Future of Cancer Treatment
Cambridge Biomedical is privileged to contribute to this exciting and promising new field of immunotherapy. Working in collaboration with researchers in the field, we are utilizing our strengths in cell-based assays to assist with the characterization of these cells.
The promise of immunotherapy
Immunotherapy empowers a patient’s own immune system to locate and destroy cancer cells. Recently, the FDA has approved significant treatment breakthroughs in the form of chimeric antigen receptor (CAR) T-cell therapies to treat certain pediatric and young adult patients with acute lymphoblastic leukemia. Another has been approved for certain types of non-Hodgkin lymphoma. Both treatments mark significant milestones in cancer therapy.
CAR T-cell therapy involves the collection and genetic modification of T-cells in order to introduce a new gene that allows the CAR T-cells to target and kill the patient’s cancer cells. The genetically engineered cells are then infused back into the patient where they begin their work to target and kill the cancer.
Looking to the future
Until recently, CAR T-cell therapy has been restricted to a small number of clinical trials involving patients with advanced cancers for which standard care had been largely ineffective. The CAR T-cell therapies, however, are showing remarkable responses in many of these patients.
We live in exciting times. Extremely promising advances in science and medicine now exist where none were available previously. There is much more to discover in the years ahead to unlock the full potential of immunotherapy as a bona fide treatment of blood cancers and, hopefully, other forms of cancer as well. Cambridge Biomedical is dedicated to specializing in this novel cancer therapy to provide the data necessary to advance this important research.